Iridex to Report First Quarter 2025 Financial Results on May 13, 2025
Iridex Corporation (Nasdaq: IRIX), a leader in laser-based medical systems for treating glaucoma and retinal diseases, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, after market close.
The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can join the call by dialing +1-888-596-4144 with conference ID: 698002.
A live and recorded webcast of the event will be accessible through the "Event Calendar" page in the "Investors" section of Iridex's website at www.iridex.com.
Iridex Corporation (Nasdaq: IRIX), leader nei sistemi medici laser per il trattamento del glaucoma e delle malattie retiniche, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 13 maggio 2025, dopo la chiusura del mercato.
La società terrà una conference call alle 14:00 PT / 17:00 ET nello stesso giorno. Gli investitori potranno partecipare chiamando il numero +1-888-596-4144 con ID conferenza: 698002.
Una diretta streaming e una registrazione dell'evento saranno disponibili nella pagina "Calendario Eventi" nella sezione "Investitori" del sito web di Iridex all'indirizzo www.iridex.com.
Iridex Corporation (Nasdaq: IRIX), líder en sistemas médicos basados en láser para el tratamiento del glaucoma y enfermedades retinianas, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 13 de mayo de 2025, después del cierre del mercado.
La empresa realizará una llamada en conferencia a las 2:00 p.m. PT / 5:00 p.m. ET ese mismo día. Los inversores pueden unirse llamando al +1-888-596-4144 con ID de conferencia: 698002.
Una transmisión en vivo y una grabación del evento estarán disponibles en la página "Calendario de Eventos" en la sección "Inversores" del sitio web de Iridex en www.iridex.com.
Iridex Corporation (나스닥: IRIX)은 녹내장 및 망막 질환 치료용 레이저 기반 의료 시스템 분야의 선두 기업으로, 2025년 1분기 재무 실적 발표를 2025년 5월 13일 장 마감 후에 예정했습니다.
회사는 같은 날 오후 2시 PT / 오후 5시 ET에 컨퍼런스 콜을 진행할 예정입니다. 투자자들은 +1-888-596-4144번으로 전화하고 회의 ID: 698002를 입력하여 참여할 수 있습니다.
이 행사의 생중계 및 녹화 웹캐스트는 Iridex 웹사이트 www.iridex.com의 "투자자" 섹션 내 "이벤트 캘린더" 페이지를 통해 접속할 수 있습니다.
Iridex Corporation (Nasdaq : IRIX), leader des systèmes médicaux laser pour le traitement du glaucome et des maladies rétiniennes, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 13 mai 2025, après la clôture du marché.
L'entreprise tiendra une conférence téléphonique le même jour à 14h00 PT / 17h00 ET. Les investisseurs peuvent rejoindre l'appel en composant le +1-888-596-4144 avec l'ID de conférence : 698002.
Une diffusion en direct ainsi qu'un enregistrement de l'événement seront accessibles via la page « Calendrier des événements » dans la section « Investisseurs » du site web de Iridex à l'adresse www.iridex.com.
Iridex Corporation (Nasdaq: IRIX), ein führendes Unternehmen für laserbasierte medizinische Systeme zur Behandlung von Glaukom und Netzhauterkrankungen, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 13. Mai 2025 nach Börsenschluss geplant.
Das Unternehmen wird am selben Tag um 14:00 Uhr PT / 17:00 Uhr ET eine Telefonkonferenz abhalten. Investoren können sich unter der Nummer +1-888-596-4144 mit der Konferenz-ID: 698002 einwählen.
Ein Live-Stream und eine Aufzeichnung der Veranstaltung sind über die Seite "Event-Kalender" im Bereich "Investoren" auf der Website von Iridex unter www.iridex.com verfügbar.
- Company maintains Nasdaq listing status (IRIX)
- Demonstrates market leadership in laser-based medical systems for glaucoma and retinal diseases
- None.
MOUNTAIN VIEW, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the first quarter 2025 and provide a business update after the close of trading on Tuesday, May 13, 2025.
The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 698002. A live and recorded webcast will be available on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2025 Iridex Corporation. All rights reserved.
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
FAQ
When will Iridex (IRIX) release Q1 2025 earnings?
How can investors join Iridex's Q1 2025 earnings call?
What time is Iridex's Q1 2025 earnings conference call?
What medical products does Iridex (IRIX) specialize in?
Where can I find Iridex's Q1 2025 earnings webcast?
